EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

被引:0
|
作者
James F. Spicer
Sarah M. Rudman
机构
[1] Kings College London,Great Maze Pond
[2] Guy’s Hospital Campus,undefined
来源
Targeted Oncology | 2010年 / 5卷
关键词
Non-small cell lung cancer; EGFR-targeted therapies; BIBW 2992;
D O I
暂无
中图分类号
学科分类号
摘要
Non-small cell lung cancer (NSCLC) is one of the most lethal types of cancer and is associated with significant mortality and morbidity worldwide. Despite improvements in conventional treatment for NSCLC, survival remains poor and improvements in patient outcome are warranted. Over recent years, basic scientific research has dramatically increased our knowledge of the pathogenesis of lung cancer and allowed us to uncover and understand the cellular pathways involved in this process. This has led to the development of therapies to selectively target these pathways. Among these, the epidermal growth factor receptor (EGFR) tyrosine kinase family and related downstream pathways play a critical role in cancer development and over recent years have become a validated target in NSCLC. The development of monoclonal antibodies and first-generation tyrosine kinase inhibitors (TKIs) targeted towards EGFR has had a considerable impact on patient outcomes. However, despite dramatic and sustained responses and the discovery of specific patient subgroups that may derive clinical benefit, resistance to first-generation EGFR TKIs inevitably develops. A new generation of agents have been developed to provide superior potency of target inhibition and further individualize the treatment of NSCLC. This article reviews EGFR-targeted therapies currently available for use and undergoing clinical development for the treatment of NSCLC, specifically focusing on next generation agents including BIBW 2992, an irreversible dual inhibitor of EGFR and HER2 kinases.
引用
收藏
页码:245 / 255
页数:10
相关论文
共 50 条
  • [1] EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
    Spicer, James F.
    Rudman, Sarah M.
    TARGETED ONCOLOGY, 2010, 5 (04) : 245 - 255
  • [2] Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR
    Spicer, James
    Calvert, Hilary
    Vidal, Laura
    Azribi, Fathi
    Perrett, Rebecca
    Shahidi, Mehdi
    Temple, Graham
    Futreal, Andrew
    De Bono, Johann
    Plummer, Ruth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S410 - S410
  • [3] Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer
    Stavridi, Flora
    Kristeleit, Rebecca
    Forster, Martin
    Ang, Joo-Ern
    Rudman, Sarah
    Uttenreuther-Fischer, Martina
    Pemberton, Karine
    Shahidi, Mehdi
    De Bono, Johann
    Spicer, James
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S444 - S444
  • [4] BIBW-2992 Dual EGFR/HER2 Inhibitor Oncolytic
    Campas, C.
    Castaner, R.
    Bolos, J.
    DRUGS OF THE FUTURE, 2008, 33 (08) : 649 - 654
  • [5] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.
    Solca, F
    Baum, A
    Guth, B
    Colbatzky, F
    Blech, S
    Amelsberg, A
    Himmelsbach, F
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [6] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    Li, D.
    Ambrogio, L.
    Shimamura, T.
    Kubo, S.
    Takahashi, M.
    Chirieac, L. R.
    Padera, R. F.
    Shapiro, G. I.
    Baum, A.
    Himmelsbach, F.
    Rettig, W. J.
    Meyerson, M.
    Solca, F.
    Greulich, H.
    Wong, K-K
    ONCOGENE, 2008, 27 (34) : 4702 - 4711
  • [7] BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    L Ambrogio
    T Shimamura
    S Kubo
    M Takahashi
    L R Chirieac
    R F Padera
    G I Shapiro
    A Baum
    F Himmelsbach
    W J Rettig
    M Meyerson
    F Solca
    H Greulich
    K-K Wong
    Oncogene, 2008, 27 : 4702 - 4711
  • [8] Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
    Bose, Prithviraj
    Ozer, Howard
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (11) : 1735 - 1751
  • [9] Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer
    Solca, F.
    Baum, A.
    Krause, M.
    Baumann, M.
    Wong, K. K.
    Greulich, H.
    Adolf, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 326 - 327
  • [10] Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model
    Shimamura, Takeshi
    Greulich, Heidi
    Solca, Flavio F.
    Wong, Kwok-Kin
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S380 - S380